Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISF35 + Pembrolizumab in Refractory Metastatic Melanoma
NCT02719015Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2018
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
01
Overview
A Phase 2 trial of ISF35 in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Planned start Mar 2018; status: withdrawn.
02
Drugs
ISF35
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02719015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719015.